Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shelly McNeil

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
The Pediatric Infectious Disease Journal|February 12, 2009
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infantsKirsten P Perrett, Matthew D Snape, Karen J Ford, et al.
Vaccines|July 24, 2020
A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18-50 Years of AgeJoanne Langley, Elodie Pastural, Scott Halperin, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|June 30, 2018
Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and OlderDesmond Curran, Lidia Oostvogels, Thomas Heineman, et al.
Plos One|July 18, 2012
Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccineGaston De Serres, Marie-Claude Gariépy, Brenda Coleman, et al.
Vaccine|February 14, 2012
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of ageScott A Halperin, Brian Ward, Curtis Cooper, et al.
JAMA|May 2, 2013
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trialSimon R M Dobson, Shelly McNeil, Marc Dionne, et al.
Plos One|September 27, 2013
Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitalsManal Tadros, Victoria Williams, Brenda L Coleman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 17, 2019
Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical TrialRobine Donken, Simon R M Dobson, Kim D Marty, et al.
The Journal of Infectious Diseases|February 25, 2016
Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 YearsThanyawee Puthanakit, Li-Min Huang, Cheng-Hsun Chiu, et al.
BMJ Open|September 30, 2025
Quadrivalent HPV Vaccine Evaluation Study with Addition of the Nonavalent Vaccine (QUEST-ADVANCE): protocol of an observational cohort studyMarit Middeldorp, Robine Donken, Aarthi Nirmal, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
The Pediatric Infectious Disease Journal|February 12, 2009
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infantsKirsten P Perrett, Matthew D Snape, Karen J Ford, et al.
Vaccines|July 24, 2020
A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18-50 Years of AgeJoanne Langley, Elodie Pastural, Scott Halperin, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|June 30, 2018
Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and OlderDesmond Curran, Lidia Oostvogels, Thomas Heineman, et al.
Plos One|July 18, 2012
Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccineGaston De Serres, Marie-Claude Gariépy, Brenda Coleman, et al.
Vaccine|February 14, 2012
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of ageScott A Halperin, Brian Ward, Curtis Cooper, et al.
JAMA|May 2, 2013
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trialSimon R M Dobson, Shelly McNeil, Marc Dionne, et al.
Plos One|September 27, 2013
Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitalsManal Tadros, Victoria Williams, Brenda L Coleman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 17, 2019
Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical TrialRobine Donken, Simon R M Dobson, Kim D Marty, et al.
The Journal of Infectious Diseases|February 25, 2016
Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 YearsThanyawee Puthanakit, Li-Min Huang, Cheng-Hsun Chiu, et al.
BMJ Open|September 30, 2025
Quadrivalent HPV Vaccine Evaluation Study with Addition of the Nonavalent Vaccine (QUEST-ADVANCE): protocol of an observational cohort studyMarit Middeldorp, Robine Donken, Aarthi Nirmal, et al.
Pageof 7